Biosims mak­ing slow progress bat­tling block­busters for mar­ket share; Fi­bro­Gen rais­ing $300M

Bloomberg has a re­port out to­day that il­lus­trates just how slow­ly biosim­i­lars are able to pen­e­trate some of the world’s biggest fran­chis­es. Some say the mar­ket is tilt­ed against them, with brand­ed drugs win­ning and keep­ing pre­ferred sta­tus, de­spite their high­er costs.

⇨ Fi­bro­Gen just joined the long line of pub­lic biotechs that have been cash­ing in on high­er stock prices. The com­pa­ny is sell­ing $300 mil­lion in shares af­ter rack­ing up some big gains.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.